DB
OCUL icon

Dmitry Balyasny’s Ocular Therapeutix OCUL Stock Holding History

Dmitry Balyasny’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.3M Sell
2,270,707
-421,915
-16% -$3.82M 0.03% 664
2026
Q1 		$22.8M Buy
2,692,622
+1,929,063
+253% +$18.4M 0.03% 631
2025
Q4 		$9.27M Sell
763,559
-1,425,717
-65% -$17.3M 0.01% 1062
2025
Q3 		$25.6M Buy
2,189,276
+1,970,983
+903% +$23.6M 0.03% 608
2025
Q2 		$2.03M Buy
218,293
+142,424
+188% +$1.11M ﹤0.01% 1722
2025
Q1 		$556K Sell
75,869
-21,684
-22% -$167K ﹤0.01% 2240
2024
Q4 		$833K Buy
+97,553
New +$952K ﹤0.01% 2006
2024
Q1 		– Sell
-89,000
Closed -$397K – 2966
2023
Q4 		$397K Buy
89,000
+36,656
+70% +$108K ﹤0.01% 2043
2023
Q3 		$164K Buy
52,344
+4,062
+8% +$16.6K ﹤0.01% 2062
2023
Q2 		$249K Buy
48,282
+32,168
+200% +$191K ﹤0.01% 2039
2023
Q1 		$84.9K Sell
16,114
-8,877
-36% -$42.2K ﹤0.01% 2332
2022
Q4 		$70.2K Buy
+24,991
New +$82.7K ﹤0.01% 2300
2022
Q3 		– Sell
-18,459
Closed -$74K – 3148
2022
Q2 		$74K Buy
+18,459
New +$69.7K ﹤0.01% 2317
2022
Q1 		– Sell
-10,912
Closed -$76K – 2733
2021
Q4 		$76K Buy
+10,912
New +$84.7K ﹤0.01% 2007
2021
Q2 		– Sell
-16,704
Closed -$274K – 2236
2021
Q1 		$274K Buy
+16,704
New +$322K ﹤0.01% 1524
2016
Q2 		– Sell
-85,000
Closed -$821K – 1362
2016
Q1 		$821K Buy
+85,000
New +$644K ﹤0.01% 799

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dmitry Balyasny's OCUL Position: Q2 2026 in Review

Dmitry Balyasny reduced its Ocular Therapeutix (OCUL) stake by 16% in Q2 2026, selling an estimated $3.82M and leaving 2,270,707 shares worth $22.3M. The position accounts for 0.03% of the portfolio, ranked #664.

Dmitry Balyasny first reported a position in OCUL in Q1 2016 and has held it in 16 quarters since. The position peaked at $25.6M in Q3 2025. 260 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Dmitry Balyasny held 2,270,707 shares of Ocular Therapeutix worth $22.3M as of Q2 2026.
  • Dmitry Balyasny sold 421,915 Ocular Therapeutix shares in Q2 2026, an estimated $3.82M.
  • Ocular Therapeutix made up 0.03% of Dmitry Balyasny's portfolio in Q2 2026, its #664 holding.
  • Dmitry Balyasny first reported a position in Ocular Therapeutix in Q1 2016 and has held it in 16 quarters since.
  • Dmitry Balyasny's Ocular Therapeutix position peaked at $25.6M in Q3 2025.
  • 260 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.